Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Cell and Gene Meeting on the Mesa 2024
19 slides from Cynata Therapeutics's conference presentation, Oct 8, 2024
Slide 1: Cynata to Present at Alliance for Regenerative Medicine Meeting
ASX ANNOUNCEMENT 8 October 2024 Cynata to Present at Alliance for Regenerative Medicine Meeting Melbourne, Australia; 8 October 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is participating in th
Slide 2: A Clinical Stage Next Generation Stem Cell Therapeutics Company
For personal use only A Clinical Stage Next Generation Stem Cell Therapeutics Company Phoenix, Arizona, 8 October 2024
Slide 3: Important information
Important information Summary information This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries Forward-looking statements (CYP, or Cynata) which is current as at 4 October 2024. This Presentation should be read in This Presentation contains certain ‘f
Slide 4: Company highlights
Company highlights Revolutionary Cymerus manufacturing platform For personal use only • Mesenchymal stem cells (MSCs)1 have shown potential to treat a wide range of illnesses2 • However, standard manufacture requires ongoing supply of donors and extensive MSC culture expansion → challenges with cons
Slide 5: Advanced and diverse clinical pipeline
Advanced and diverse clinical pipeline Indication Trial phase Upcoming catalysts* Market opportunity For personal use only Acute Graft vs Host Disease (aGvHD) Enrolment completion – Q4 2024 Phase 2 Cynata Sponsored CYP-001 US$600m1 FDA Orphan Designation ongoing Results – 2H 2025 Phase 1 Diabetic Fo
Slide 6: Revolutionary iPSC-based Cymerus Manufacturing Platform
For personal use only Revolutionary iPSC-based Cymerus Manufacturing Platform
Slide 7: Therapeutic potential of MSCs
Therapeutic potential of MSCs Mesenchymal stem cells1 (MSCs): • Promote an immunomodulatory For personal use only environment2 • The “sensor and switcher of the immune system”3 • Promote tissue repair and regeneration • Can be used without matching donors to recipients • Can be engineered to express
Slide 8: Advantages of iPSC-based platform
Advantages of iPSC-based platform Induced pluripotent stem cells (iPSCs): For personal use only • Mature adult cells reprogrammed to become pluripotent, which means: • Effectively limitless proliferation capacity • Potential to differentiate into any adult cell type (including MSCs) • Similar proper
Slide 9: Conventional MSC process vs Cymerus iPSC-based process
Conventional MSC process Major challenges: Ongoing need • MSCs undergo functional changes MSC isolation Culture expansion and loss of potency during for new donors extensive culture expansion • Continuously finding and testing new For personal use only donors is logistically challenging • Inter-dono
Slide 10: Compelling Clinical Data
For personal use only Compelling Clinical Data
Slide 11: CYP-001: Two Nature Medicine publications
CYP-001: Two Nature Medicine publications • CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of GvHD • Phase 1 trial of CYP-001 was the first completed For personal use only clinical trial worldwide with any iPSC-derived product 10 1. CYP-001 is Cynata’s Cymerus iPSC-
Slide 12: aGvHD Phase 1 clinical trial - results
aGvHD | Phase 1 clinical trial - results Product: CYP-001 (Cymerus MSCs for intravenous infusion) Trial conducted in 15 patients with steroid-resistant aGvHD (SR-aGvHD) For personal use only • CYP-001 was shown to be Day 100 complete 53% Day 100 overall 87% 2yr survival 60% safe and well tolerated,
Slide 13: Ph1 SR-aGvHD results compared to other therapies
Ph1 SR-aGvHD results compared to other therapies “Best available therapy” For personal use only CYP-001 (Ph 1) Ruxolitinib (Ph 3) controls (Ph 3) Day 28 Overall Response 67% 62% 39% Day 56-60* Overall Response 73% 40% 22% Overall Survival 60% after 2 years 38% after 18 months 36% after 18 months No
Slide 14: CYP-006TK – a novel topical MSC product
CYP-006TK – a novel topical MSC product • CYP-006TK utilises a For personal use only iPSC-derived MSCs proprietary surface-coating, optimised for the delivery of MSCs directly to the wound bed • Technology exclusively licenced to Cynata by Tekcyte Limited (agreement for Cynata to acquire this IP out
Slide 15: DFU Phase 2 clinical trial – initial data
DFU | Phase 1 clinical trial – initial data Product: CYP-006TK (topical Cymerus MSC wound dressing) • Ongoing trial in non-healing diabetic foot ulcer (DFU) • Patients randomised to receive standard of care (SoC) or CYP-006TK for 4 weeks, followed by SoC For personal use only • In the first 16 patie
Slide 16: Outlook
For personal use only Outlook
Slide 17: Upcoming catalysts
Upcoming catalysts* Results of three randomised controlled clinical trials expected between late 2024 and early 2026 Phase 1/2 First Results For personal use only kidney patient (Cohort 1) transplant enrolled Phase 2 Enrolment Results aGvHD complete Completion Phase 1 Results Results of enrolment DF
Slide 18: Summary
Summary Next generation stem • Leading platform technology in burgeoning stem cell sector cell company • Diverse and highly credentialed leadership team with proven experience For personal use only • Cymerus manufacturing technology protected by robust patent portfolio Scalable manufacturing • Enabl
Slide 19: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne Victoria 3121 Australia cynatatherapeutics info@cynata.com @cynatastemcells www.cynata.com cynata-therapeutics
Cynata Therapeutics — Cell and Gene Meeting on the Mesa 2024 on 6ix